Alcista
$7.26
Precio del escenario
$13.300
-0.491 (-3.69%)Al cierre
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
Bioventus Inc is a good buy right now, given its current price of $13.30 and a forward P/E of 14.79, which suggests the stock is reasonably valued compared to its earnings potential. Additionally, the company has shown a significant year-to-date change of +84.47%, indicating strong momentum. The main risk is the recent strategic review initiated by the Board, which could lead to uncertainty regarding the company's future direction.
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Bravura Solutions Reports Significant Revenue Growth

Biotech Stocks Reach 52-Week Highs Driven by Earnings

Bioventus Q2 2026 Earnings Call Highlights

Bioventus Q2 Earnings Report Analysis

Bioventus Reports Significant Earnings Growth in Q2
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Bioventus Inc is a good buy right now, given its current price of $13.30 and a forward P/E of 14.79, which suggests the stock is reasonably valued compared to its earnings potential. Additionally, the company has shown a significant year-to-date change of +84.47%, indicating strong momentum. The main risk is the recent strategic review initiated by the Board, which could lead to uncertainty regarding the company's future direction.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.